5.7: A decision that depended on the manufacturing system

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    5.7: A decision that depended on the manufacturing system

    Public FDA statements from April and June 2021 describe separate decisions about manufacturing conditions and individual batches at Emergent BioSolutions. The account below follows those events. The SIPOC interpretation is a teaching analysis, rather than a map published by the company.

    In spring 2021, COVID-19 vaccine manufacturing carried urgent public expectations. At Emergent BioSolutions in Baltimore, work intended to support the Johnson & Johnson vaccine reached a pause. On April 21, FDA reported that its inspection had raised concerns about the facility’s processes. At the agency’s request, Emergent agreed to stop new production while potential quality issues were addressed.

    Batch decisions and facility review.pngThe review reached beyond a finished sample. FDA described examining manufacturing records, training, operations, production, testing, and quality systems. Existing material would need additional evaluation before possible distribution. FDA also stated that vaccine manufactured at the plant had not been distributed for use in the United States as of that announcement.

    The review then produced different decisions. On June 11, 2021, FDA authorized two batches of vaccine drug substance for use under the Janssen emergency use authorization (EUA), after reviewing facility records and manufacturer quality-test results. Drug substance is an intermediate used to make the finished vaccine. Several other batches were unsuitable, and additional batches remained under review. FDA was not yet ready to include the facility itself as an authorized manufacturing site in the EUA.

    Permission to use the two batches did not mean that all facility questions were resolved or that all batches were acceptable. FDA described its decision in the context of its evidence review and the COVID-19 public health emergency. The batch decisions and the facility decision answered related but distinct questions.

    Through a teaching SIPOC lens, materials and records are inputs to defined manufacturing or review processes; batch information and disposition decisions become outputs used by the next process. The exact map depends on its boundary. Patients and the public are affected downstream. The case illustrates why production, testing, documentation, and authority must connect. It does not establish that Emergent used SIPOC or that a diagram alone would have prevented the problems.


    This page titled 5.7: A decision that depended on the manufacturing system was last modified on Fri, 06 Nov 2026 11:42:06 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.